Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells

Oncogene

Volumn 32, Issue 37, 2013, Pages 4366-4376

  Martino, J J ^a   Wall, B A ^a   Mastrantoni, E ^a,b   Wilimczyk, B J ^a   La Cava, S N ^a   Degenhardt, K ^c   White, E ^d,e   Chen, S ^a,d  

^a RUTGERS UNIVERSITY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Touro College of Osteopathic Medicine   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e Rutgers University   (United States)

Author keywords

Carcinoma; Cell transformation; Glutamatergic signaling; Grm1; Kidney epithelial cells; Oncogene

Indexed keywords

COMPLEMENTARY DNA; METABOTROPIC RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL LINE; CELL PROLIFERATION; CELL STRAIN IBMK; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY CELL; MALIGNANT TRANSFORMATION; MELANOMA; MOUSE; NONHUMAN; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECOND MESSENGER;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLUTAMIC ACID; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENES; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, METABOTROPIC GLUTAMATE; RILUZOLE;

EID: 84884203979     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.471     Document Type: Article

References (70)

1. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D. Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci 2007; 28: 206-213.
2. Frati C, Marchese C, Fisichella G, Copani A, Nasca MR, Storto M et al. Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J Cell Physiol 2000; 183: 364-372.
3. Genever PG, Maxfield SJ, Kennovin GD, Maltman J, Bowgen CJ, Raxworthy MJ et al. Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. J Invest Dermatol 1999; 112: 337-342.
4. Tong Q, Ouedraogo R, Kirchgessner AL. Localization and function of group. III metabotropic glutamate receptors in rat pancreatic islets. Am J Physiol Endocrinol Metab 2002; 282: E1324-E1333.
5. Storto M, Capobianco L, Battaglia G, Molinaro G, Gradini R, Riozzi B et al. Insulin secretion is controlled by mGlu5 metabotropic glutamate receptors. Mol Pharmacol 2006; 69: 1234-1241.
6. Gill SS, Pulido OM, Mueller RW, McGuire PF. Immunochemical localization of the metabotropic glutamate receptors in the rat heart. Brain Res Bull 1999; 48: 143-146.
7. Storto M, de Grazia U, Knopfel T, Canonico PL, Copani A, Richelmi P et al. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. Hepatology 2000; 31: 649-655.
8. Melchiorri D, Cappuccio I, Ciceroni C, Spinsanti P, Mosillo P, Sarichelou I et al. Metabotropic glutamate receptors in stem/progenitor cells. Neuropharmacology 2007; 53: 473-480.
9. Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S et al. Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J 2006; 25: 4175-4186.
10. Young VR, Ajami AM. Glutamate: an amino acid of particular distinction. J Nutr 2000; 130: 892S-900S.
11. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003; 34: 108-112.
12. Marin Y, Chen S. Involvement of metabotropic glutamate receptor 1, a G-proteincoupled receptor, in melanoma development. J Mol Med 2004; 82: 735-749.
13. Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J et al. Development of heritable melanoma in transgenic mice. J Invest Dermatol 1998; 110: 247-252.
14. Shin SS, Martino JJ, Chen S. Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology 2008b; 55: 396-402.
15. Namkoong J, Shin SS, Lee HJ, Marin YE, Wall BA, Goydos JS et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007; 67: 2298-2305.
16. Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A et al. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 2009; 15: 3896-3902.
17. Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V et al. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet 2011; 43: 1119-1126.
18. Choi KY, Chang K, Pickel JM, Badger II JD, Roche KW. Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice. Proc Natl Acad Sci USA 2011; 108: 15219-15224.
19. Sharon D, Vorobiov D, Dascal N. Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes. J Gen Physiol 1997; 109: 477-490.
20. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000; 130: 1007S-1015S.
21. Hoogduijn MJ, Hitchcock IS, Smit NP, Gillbro JM, Schallreuter KU, Genever PG. Glutamate receptors on human melanocytes regulate the expression of MiTF. Pigment Cell Res 2006; 19: 58-67.
22. Milligan G. Receptors as kissing cousins. Science 2000; 288: 65-67.
23. Degenhardt K, White E. A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin Cancer Res 2006; 12: 5298-5304.
24. Degenhardt K, Chen G, Lindsten T, White E. BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell 2002; 2: 193-203.
25. Ferraguti F, Crepaldi L, Nicoletti F. Metabotropic glutamate 1 receptor: current concepts and perspectives. Pharmacol Rev 2008; 60: 536-581.
26. Marin YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M et al. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. Cell Signaling 2006; 18: 1279-1286.
27. Shin SS, Wall B, Goydos JS, Chen S. AKT2 is a downstream target of metabotropic glutamate receptor 1 (mGlu1). Pigment Cell Melanoma Res 2010; 23: 103-111.
28. Degenhardt K, Sundararajan R, Lindsten T, Thompson C, White E. Bax and Bak independently promote cytochrome C release from mitochondria. J Biol Chem 2002a; 277: 14127-14134.
29. Anglard P, Trahan E, Liu S, Latif F, Merino MJ, Lerman MI et al. Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res 1992; 52: 348-356.
30. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 2001; 59: 965-973.
31. Prezeau L, Gomeza J, Ahern S, Mary S, Galvez T, Bockaert J et al. Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol 1996; 49: 422-429.
32. Jong YJ, Schwetye KE, O'Malley KL. Nuclear localization of functional metabotropic glutamate receptor mGlu1 in HEK293 cells and cortical neurons: role in nuclear calcium mobilization and development. J Neurochem 2007; 101: 458-469.
33. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005a; 436: 117-122.
34. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH et al. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991; 47: 227-237.
35. Julius D, Livelli TJ, Jessell TM, Axel R. Extopic expresion of the serotonin 1c receptor and the triggering of malignant transformation. Science 1989; 244: 1057-1062.
36. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci 1991; 88: 4703-4707.
37. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008; 23: 1-9.
38. Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal 2011; 23: 1515-1527.
39. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822.
40. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
41. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011; 3: 192-222.
42. American Cancer Society. Cancer Facts & Figures. American Cancer Society: Atlanta, 2012.
43. Bracarda S. Metastatic renal cell carcinoma: pathogenesis and the current medical landscape. Eur Urol Suppl 2009; 8: 787-792.
44. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103: 714-736.
45. Mathew A, Devesa SS, Fraumeni Jr JF, Chow WH. Global increases in kidney cancer incidence, 1973-1992. Eur J Cancer Prev 2002; 11: 171-178.
46. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001; 145: 981-985.
47. Tihan T, Filippa DA. Coexistence of renal cell carcinoma and malignant lymphoma. A causal relationship or coincidental occurrence? Cancer 1996; 77: 2325-2331.
48. Teh J, Chen S. Metabotropic glutamate receptors and cancerous growth. WIREs Membr Transp Signal 2012; 1: 211-220.
49. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10: 47-60.
50. D'Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V et al. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 2003; 84: 1288-1295.
51. Iacovelli L, Arcella A, Battaglia G, Pazzaglia S, Aronica E, Spinsanti P et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J Neurosci 2006; 26: 8388-8397.
52. Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate Jr CA. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009; 15: 1595-1611.
53. Recasens M, Guiramand J, Aimar R, Abdulkarim A, Barbanel G. Metabotropic glutamate receptors as drug targets. Curr Drug Targets 2007; 8: 651-681.
54. Wieronska JM, Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 2009; 55: 85-97.
55. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; CD001447.
56. Tripathi VB, Al-Chalabi A. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol Disord Drug Targets 2008; 7: 11-19.
57. Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA et al. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010; 130: 2240-2249.
58. Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg SA, Chan JL-K et al. Glutamatergic pathway targeting in melanoma; single agent and combinatorial therapies. Clin Cancer Res 2011; 17: 7080-7092.
59. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-1015.
60. Seidlitz EP, Sharma MK, Saikali Z, Ghert M, Singh G. Cancer cell lines release glutamate into the extracellular environment. Clin Exp Metastasis 2009; 26: 781-787.
61. Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/ glutamate antiporter. Biochem Biophys Res Commun 2010; 391: 91-95.
62. Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 2012; 132: 565-573.
63. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-1344.
64. Zhu H, Ryan K, Chen S. Cloning of novel splice variants of mouse mGluR1. Brain Res Mol Brain Res 1999; 73: 93-103.
65. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003; 31: e77.
66. Wangari-Talbot J, Wall BA, Goydos JS, Chen S. Functional Effects of GRM1 Suppression in Human Melanoma Cells. Mol Cancer Res (e-pub ahead of print 13 July 2012; doi:10.1158/1541-7786.MCR-12-0158).
67. Thandi S, Blank JL, Challiss RA. Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem 2002; 83: 1139-1153.
68. Cohen-Solal KA, Crespo-Carbone SM, Namkoong J, Mackason KR, Roberts KG, Reuhl KR et al. Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res 2002; 15: 282-289.
69. Wu TY, Saw CL, Khor TO, Pung D, Boyanapalli SS, Kong AN. In vivo pharmacodynamics of indole-3-carbinol in the inhibition of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: Involvement of Nrf2 and cell cycle/apoptosis signaling pathways. Mol Carcinog 2012; 51: 761-770.
70. Stepulak A, Sifringer M, Rzeski W, Endesfelder S, Gratopp A, Pohl EE et al. NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. Proc Natl Acad Sci USA 2005; 102: 15605-15610.